Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
doi: 10.2147/DDDT.S556231, Summary Keywords fibrosis, glucagon-like peptide-1 receptor agonists, inflammation, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease Citation Lu X and Yang L (2026) Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research
Perreault, L., Davies, M., Frias, J
Results highlight that consumers with GLP-1 medication experience are much more likely to expect the drugs will have an economic impact on players across the food system
By adjusting lipid energy use efficiency and the metabolite profile, the tolerance of children to unstable factors is improved
This tiered approach allows the body to upregulate GLP-1 receptor signaling gradually
